High Sensitivity C-Reactive Protein Increases the Risk of Carotid Plaque Instability in Male Dyslipidemic Patients.
atherosclerosis
cardiovascular risk factors
carotid plaque
dyslipidemic patients
hs-CRP
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
15 Nov 2021
15 Nov 2021
Historique:
received:
23
09
2021
revised:
11
11
2021
accepted:
13
11
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
The aim of this study was to evaluate how the high sensitivity C-reactive protein (hs-CRP) values influence the risk of carotid plaque instability in association with other cardiovascular risk factors. One hundred and fifty-six carotid plaques from both symptomatic and asymptomatic patients requiring surgical carotid endarterectomy were retrospectively collected. According to the modified American Heart Association, atherosclerosis plaques have been histologically distinguished into unstable and stable. The following anamnestic and hematochemical data were also considered: age, gender, hypertension, diabetes mellitus, smoking habit, therapy, low-density lipoprotein (LDL)-C, kidney failure and hs-CRP. The results of our study clearly show that high levels of hs-CRP significantly increase the carotid plaque instability in dyslipidemic patients. Specifically, a 67% increase of the risk of carotid plaque instability was observed in patients with high LDL-C. Therefore, the highest risk was observed in male dyslipidemic patients 2333 (95% CI 0.73-7.48) and in aged female patients 2713 (95% CI 0.14-53.27). These data strongly suggest a biological relationship between the hs-CRP values and the alteration of lipidic metabolism mostly in male patients affected by carotid atherosclerosis. The measurement of hs-CRP might be useful as a potential screening tool in the prevention of atheroscletotic disease.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of this study was to evaluate how the high sensitivity C-reactive protein (hs-CRP) values influence the risk of carotid plaque instability in association with other cardiovascular risk factors.
METHODS
METHODS
One hundred and fifty-six carotid plaques from both symptomatic and asymptomatic patients requiring surgical carotid endarterectomy were retrospectively collected. According to the modified American Heart Association, atherosclerosis plaques have been histologically distinguished into unstable and stable. The following anamnestic and hematochemical data were also considered: age, gender, hypertension, diabetes mellitus, smoking habit, therapy, low-density lipoprotein (LDL)-C, kidney failure and hs-CRP.
RESULTS
RESULTS
The results of our study clearly show that high levels of hs-CRP significantly increase the carotid plaque instability in dyslipidemic patients. Specifically, a 67% increase of the risk of carotid plaque instability was observed in patients with high LDL-C. Therefore, the highest risk was observed in male dyslipidemic patients 2333 (95% CI 0.73-7.48) and in aged female patients 2713 (95% CI 0.14-53.27).
DISCUSSION
CONCLUSIONS
These data strongly suggest a biological relationship between the hs-CRP values and the alteration of lipidic metabolism mostly in male patients affected by carotid atherosclerosis. The measurement of hs-CRP might be useful as a potential screening tool in the prevention of atheroscletotic disease.
Identifiants
pubmed: 34829465
pii: diagnostics11112117
doi: 10.3390/diagnostics11112117
pmc: PMC8624324
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cerebrovasc Dis. 2009;27(4):392-7
pubmed: 19276622
J Nucl Med. 2007 Nov;48(11):1800-15
pubmed: 17942804
JAMA. 2004 Oct 20;292(15):1845-52
pubmed: 15494582
Int J Mol Sci. 2017 Sep 22;18(10):
pubmed: 28937652
Appl Immunohistochem Mol Morphol. 2021 Nov-Dec 01;29(10):741-749
pubmed: 34039839
J Vasc Surg. 2013 Feb;57(2):338-44
pubmed: 23058720
N Engl J Med. 2020 Jan 2;382(1):9
pubmed: 31738483
Nature. 2000 Sep 14;407(6801):233-41
pubmed: 11001066
Curr Opin Lipidol. 2021 Oct 1;32(5):286-292
pubmed: 34392272
Nat Immunol. 2011 Mar;12(3):204-12
pubmed: 21321594
Cardiovasc Diabetol. 2021 May 6;20(1):98
pubmed: 33957931
Stroke. 2016 Dec;47(12):2952-2958
pubmed: 27803393
Atherosclerosis. 2017 Aug;263:293-300
pubmed: 28728065
Clin Sci (Lond). 2018 Jun 21;132(12):1243-1252
pubmed: 29930142
Lancet Glob Health. 2020 May;8(5):e721-e729
pubmed: 32353319
Int J Mol Sci. 2021 Jan 01;22(1):
pubmed: 33401449
Stroke. 2004 Jul;35(7):1619-24
pubmed: 15155967
Nutr Metab Cardiovasc Dis. 2019 Dec;29(12):1330-1336
pubmed: 31653516
J Neurol. 2009 May;256(5):783-91
pubmed: 19240956
Cardiovasc Diabetol. 2018 Mar 29;17(1):46
pubmed: 29598820
Atherosclerosis. 2011 Oct;218(2):356-62
pubmed: 21813127
J Pharm Pharm Sci. 2018;21(1):496-503
pubmed: 30496036
Arch Med Sci. 2013 Apr 20;9(2):254-60
pubmed: 23671435
Vasc Endovascular Surg. 2008 Apr-May;42(2):122-7
pubmed: 18421029
Clin Chem. 1972 Jun;18(6):499-502
pubmed: 4337382
Nutr Metab Cardiovasc Dis. 2017 Sep;27(9):768-774
pubmed: 28739184
Arterioscler Thromb Vasc Biol. 2000 May;20(5):1262-75
pubmed: 10807742
J Nucl Cardiol. 2021 Jul 27;:
pubmed: 34318395
Lancet. 2019 Dec 14;394(10215):2173-2183
pubmed: 31810609
Curr Drug Targets. 2011 May;12(5):647-60
pubmed: 21039336
Int J Cardiol. 2012 Mar 8;155(2):309-11
pubmed: 22192293
Eur Heart J. 2020 Aug 14;41(31):2997-3004
pubmed: 32402086
Aging Dis. 2019 Feb 01;10(1):71-81
pubmed: 30705769
Atherosclerosis. 2021 May;325:69-74
pubmed: 33894597
Nature. 2002 Dec 19-26;420(6917):868-74
pubmed: 12490960
Lancet. 2012 Jan 14;379(9811):165-80
pubmed: 21840587
Eur Heart J. 2017 Aug 21;38(32):2459-2472
pubmed: 28444290
Front Immunol. 2021 Jan 29;11:622772
pubmed: 33584725
Calcif Tissue Int. 2018 May;102(5):592-606
pubmed: 29313071
Atherosclerosis. 2013 Jul;229(1):124-9
pubmed: 23578355